Latest Breaking News On - Stephenson cancer center - Page 6 : vimarsana.com

Ovarian cancer treatment on fast track for FDA approval as chemo alternatives emerge: 'We're making progress'

Ovarian cancer drug RC88 by RemeGen received FDA approval for Phase 2 clinical trials. Gynecologic oncologist Dr. Brian Slomovitz and other experts weigh in on the drug's potential.

OU research focuses on innovative combination of imaging techniques to detect pancreatic cancer

Researchers at OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences have embarked on a revolutionary new research study that could improve the detection of a deadly disease -; pancreatic cancer -; and give patients a chance to live longer, healthier lives.

Ovarian cancer treatment on fast track for FDA approval as chemo alternatives emerge: 'We're making progress'

Ovarian cancer treatment on fast track for FDA approval as chemo alternatives emerge: 'We're making progress'

Preclinical Study Reveals Potential Role for GLP-Agonists in Endometrial Cancer

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Addition of immunotherapy to perioperative cancer treatment linked to more toxicity

Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Oklahoma researchers develop effective ovarian cancer treatment

OU Health announced that researchers at the Stephenson Cancer Center are playing a major role in making a new treatment.

Global Ovarian Cancer Drug Trial Led by Stephenson Researcher

Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.